Perspectives from EPA’s Endocrine Disruptor Screening Program

Slides:



Advertisements
Similar presentations
1 Consumer Exposure Assessment at the U.S. Environmental Protection Agency: A ccomplishments and Opportunities for Global Collaboration Thomas Brennan.
Advertisements

1 EPAs 2008 Report on the Environment Denice M. Shaw, PhD U.S. Environmental Protection Agency Office of Research and Development National Center for Environmental.
Jim Jones Acting Assistant Administrator Office of Chemical Safety & Pollution Prevention 1.
UNEP Advisory Group Meeting Geneva, Switzerland December 12, 2014
Richard A. Becker, Ph.D., D.A.B.T American Chemistry Council Arlington, Virginia Comments on “Dose Setting” EDMVS Meeting July 23-24, 2002.
Session III: Assessing Cumulative Effects of Endocrine Active Substances 9:15 - 9:30 Introduction” Rick Becker (Session Chair and Panel Moderator) 9:30.
Carcinogen Classification Criteria Patricia Richter Ph.D., DABT Tobacco Products Scientific Advisory Committee June 8, 2010.
Priority-setting for the Endocrine Disruptor Screening Program: Pesticide Active Ingredients Penelope A. Fenner-Crisp Office of Pesticide Programs U.S.
National Pesticide Program A New Toxicology Testing Paradigm: Meeting Common Needs Steven Bradbury, Director Environmental Fate and Effects Division Office.
William H. Farland, Ph.D. Acting Deputy Assistant Administrator for Science Office of Research and Development U.S. ENVIRONMENTAL PROTECTION AGENCY Biomarkers:
EDSP Validation Gary E.Timm Senior Technical Advisor Office of Science Coordination and Policy U.S. Environmental Protection Agency.
What Do Toxicologists Do?
WILLIAM JORDAN DEPUTY DIRECTOR, OFFICE OF PESTICIDE PROGRAMS UNITED STATES ENVIRONMENTAL PROTECTION AGENCY US EPA Regulation of Endocrine Disrupting Chemicals.
Guidelines for State School Environmental Health Programs EISA Sec. 504.
The Toxic Substances Control Act (TSCA) Interagency Testing Committee (ITC)
June 16-19, USEPA Cancer Guidelines: Mode of Carcinogenic Action 1 ICABR – Impacts of the Bioeconomy on Agricultural Sustainability, the Environment.
EPA Office of Water Source Water Protection Initiative Elizabeth Corr, Associate Director Drinking Water Protection Div. Office of Ground Water and Drinking.
Criteria for Screens— Review of the EDSTAC Recommendations Presentation to the EDMVS July 23, 2002.
TCEQ/NUATRC Air Toxics Workshop: Session V – Human Health Effects Nathan Pechacek, M.S. Toxicology Section Texas Commission on Environmental Quality
Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.
The Role of Research in the Business of the Environmental Protection Agency Steven Bradbury, Director Environmental Fate & Effects Division Office of Pesticide.
Quill Law Group LLC1 EDSP Implementation Business and Legal Considerations Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington, DC
Quill Law Group LLC1 EDSP Compliance EDSP Phase 2 Policies and Procedures Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington, DC
Status of the U.S. Endocrine Disruptor Screening Program (EDSP) Status of the U.S. Endocrine Disruptor Screening Program (EDSP) September
Regulatory Controls PBT Strategy Team Great Lakes Regional Collaboration February 22, 2005.
EPA’s New Chemical List: Who, How, Possible Challenges & Responses, Listing Criteria Richard Becker, Ph.D., DABT American Chemistry Council December 13,
Office of Pesticide Programs 21st Century Screening Assessment of Pesticides – A Regulatory View Vicki Dellarco, Ph.D. Senior Science Advisor Office of.
EDSP’s Approach to Test Protocol Validation Office of Science Coordination and Policy U.S. Environmental Protection Agency.
Quill Law Group LLC1 Endocrine Disruption and Personal Care Products --- Legislative Developments Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington,
Environmental Protection in the United States Christopher Green U.S. Embassy July 13, 2006.
Quill Law Group LLC1 EDSP Compliance Timing, Procedural and Legal Issues Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington, DC
Multimedia Assessment for New Fuels: Stakeholders’ Meeting September 13, 2005 Sacramento, CA Dean Simeroth, California Air Resources Board Dave Rice, Lawrence.
Slide 1 of 24 EPA’s Endocrine Disruptor Screening Program (EDSP) Use of Exposure Data in Priority Setting Bill Wooge Office of Science Coordination and.
Forging Partnerships on Emerging Contaminants November 2, 2005 John Vandenberg Associate Director for Health National Center for Environmental Assessment.
1 Tier 1 EDSP: Other Scientifically Relevant Information Barbara Neal Exponent December 13, 2010.
1 EPA Regulatory Authority and PPCPs Octavia Conerly Health and Ecological Criteria Division Office of Water Office of Water October 26, 2005 October 26,
Tribal Science Council Regaining and Protecting “Regaining and Protecting Tribal Culture through Science Tribal Culture through Science” 6th Annual New.
Module 3 Risk Analysis and its Components. Risk Analysis ● WTO SPS agreement puts emphasis on sound science ● Risk analysis = integrated mechanism to.
Food Quality Protection Act of 1996 by: Bjorn Bookser period 2.
Regulatory Processes for Pesticides Mark Hartman Antimicrobials Division (AD) Office of Prevention, Pesticides and Toxic Substances United States Environmental.
International Society of Regulatory Toxicology and Pharmacology 2009 Endocrine Workshop The Endocrine Disruptor Screening Program: What Can Screening Results.
Development of a Common Effects Methodology for OW and OPP EPA Development Team Office of Pesticide Programs Office of Water Office of Research and Development.
Communications and the Endocrine Disruptor Screening Program ISRTP Workshop December 13, 2010.
Quill Law Group LLC1 EDSP Implementation Business and Legal Considerations Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington, DC
State of California Department of Alcohol and Drug Programs State Incentive Grant Project Overview Michael Cunningham Deputy Director, Program Services.
Christopher J. Borgert, PhD Weight of Evidence Determinations for EPA’s EDSP ISRTP Workshop, December 13 Lister Hill Auditorium, Bethesda, MD.
Introduction to Session II: Incorporating Existing Data into the EDSP Erik R. Janus Director, Human Health Policy CropLife America.
Risk Assessment.
Public Health and Risk Assessment (2nd of 10 Lectures on Toxicologic Epidemiology) Michael H. Dong MPH, DrPA, PhD  readings.
1 Nanoscale Materials Stewardship Program Environmental Summit May 20, 2008 Jim Alwood Chemical Control Division Office of Pollution Prevention and Toxics.
OECD’s work on Adverse outcome pathways
Overview FDA Food Safety Modernization Act Section 104
EDSP Implementation: Concerns for the Pesticide Industry ISRTP 2009 Endocrine Workshop: The Endocrine Disruptor Screening Program: What Can Screening Results.
Perspective on the current state-of-knowledge of mode of action as it relates to the dose response assessment of cancer and noncancer toxicity Jennifer.
New Ecological Science Advice for Ecosystem Protection The EPA Science Advisory Board (SAB) Staff Office supports three external scientific advisory committees.
Food Additives Project
Endocrine Disruptor Screening and Testing: An Industry Update
Preventing Exposure to Lead in Drinking Water
Safe Drinking Water Act , CCL and Perchlorate
FIFRA SAP Meeting February 2, 2010
Risk Assessment Dec 4 -6, 2006.
Decision Contexts in a Changing Toxicology Paradigm
Preventing Exposure to Lead in Drinking Water
Regulatory Sciences and Government Affairs
Comments on Using Existing Data for the Endocrine Screening Testing Lorenz Rhomberg, PhD Principal Gradient ISRTP 2009 Endocrine Workshop.
A Regional Perspective on Developing Children’s Environmental Health Indicators: The North American Experience Workshop on Environmental Threats to the.
Food Quality Protection Act of 1996
PFAS Background and Action Plan
Introduction to Risk Assessment
Presentation transcript:

Perspectives from EPA’s Endocrine Disruptor Screening Program David J. Dix, Ph.D. Director, Office of Science Coordination and Policy Office of Chemical Safety and Pollution Prevention Email: dix.david@epa.gov CLA April 10, 2014

1996 Legislative Mandate 1996 Federal Food, Drug and Cosmetic Act, section 408(p) Requires the U. S. EPA to develop a screening program using appropriate validated test systems and other scientifically relevant methods to determine whether certain substances may have an effect in humans that is similar to an effect produced by a naturally occurring estrogen, or other such endocrine effect as the Administrator may designate. 1996 Safe Drinking Water Act Amendments, section 1457 Testing of chemical substances that may be found in sources of drinking water, if substantial human populations may be exposed.

1998 Endocrine Disruptor Screening and Testing Advisory Committee (EDSTAC) EDSTAC Key Recommendations: Expand Protection to Include Human Health and Wildlife Include Estrogen, Androgen and Thyroid Pathways Develop a Two-Tiered Screening and Testing Program: EDSTAC Conceptual Framework: Tier 1 Screening for Potential to Interact Potential to interact with the estrogen, androgen or thyroid hormone systems Tier 2 Testing to determine Interaction with the endocrine system If endocrine-mediated adverse effects then quantify dose-response relationship

EDSP Implementation EPA has reviewed ~500 studies required on EDSP List 1 Initiated WOE evaluations of 52 chemicals for estrogen, androgen and thyroid (E, A & T) interactions Agency currently reviewing Tier 1 data and other scientifically relevant information (OSRI) Initial WOE evaluation of 12 chemicals completed Based on the first WOE reviews: EPA may not require many (if any) Tier 2 studies to assess human health risks for EDSP List 1 pesticidal chemical Tier 2 ecological studies may be required for some chemicals

EDSP Chemical Universe EDSP Implementation EDSP List 2 Chemicals Draft EDSP List 2 chemicals for Tier 1 screening released (2010) EPA issued revised EDSP List 2 with 109 chemicals (2013) - Selection based on registration review schedule of 41 pesticidal chemicals and 68 drinking water contaminants EDSP Chemical Universe 10,000 chemicals (FIFRA & SDWA) EDSP List 2 109 Chemicals EDSP List 1 52 Chemicals Slide 6

Evolution of the EDSP Based on current pace it could take decades to screen all 10,000 chemicals for potential to interact with the endocrine system Recent advances in computational toxicology herald an important “evolutionary turning point” and an accelerated pace of screening and testing To address thousands of chemicals for potential to interact with the endocrine system, we must implement a more strategic approach to prioritize chemicals for targeted screening

Utility of Computational Toxicology Rapidly screen chemicals and use predictive models to evaluate thousands of chemicals for potential risk to human health and environment Increase capacity to prioritize, screen and predict chemical toxicity and exposure Overcome throughput limitations of traditional chemical toxicity testing, augmenting current data sources Eventual replacement of some existing tests with non-animal alternatives Partner across EPA, with other federal agencies, state agencies, industry and non-governmental organizations to validate and apply tools Provide open access to data and adverse outcome pathway (AOP) risk predictions

Risk-Based Prioritization ToxCast Expanding use of CompTox (Phys-chem properties, QSARS, etc.) to support risk based prioritization Transparent and collaborative ExpoCast Rapid exposure estimation based on readily available chemical use and production data Use toxicokinetics to bridge in vitro, concentration-based ToxCast data to in vivo, dose-based Exposures from ExpoCast ToxCast High Throughput Risk-Based Prioritization ExpoCast

Risk-Based Prioritization EDSP Chemical Universe n = 10,000 Prioritize and target screening and testing of List 2 chemicals using new CompTox tools Risk-based prioritization of 10,000 chemical universe for List 3 EDSP Universe (phys-chem filters) n = ~5000 Risk-Based Prioritization Lower Priority Chemicals EDSP List 2 109 Chemicals EDSP List 3 EDSP List 1 52 Chemicals Exposure-based lists CompTox → Risk-Based Prioritization

Adverse Outcome Pathways (AOP) AOP Support: Developing and applying lower tiered tests & non-animal models e.g., QSAR, in vitro, HTS Forming Chemical Categories & Read Across methods Better dosimetry and biomarkers in experimental studies, epidemiology, population monitoring Species extrapolation

EDSP Relevant AOP Estrogen, Androgen and Thyroid (EAT) Risk-based AOP prioritization and assessment requires Measurement or prediction of in life dose-response Monitoring or prediction of real-world exposures Linkages between exposure – activity - adversity Consistent with 2013 SAP recommendations on use of Physical Chemical Properties, QSAR/HTS, and Exposure Predictions EDSP21 is focused on developing high throughput, risk-based AOP methods to prioritize targeted testing

Current Status of EDSP Prioritization and Screening 52 List 1 chemicals with complete Tier 1 datasets undergoing weight-of-evidence determination of EAT endocrine activity and possible Tier 2 testing 109 List 2 chemicals going through OMB review for Tier 1 screening EDSP Universe of chemicals being prioritized for EDSP screening using computational toxicology and other tools Science Advisory Panel peer reviews being planned: Exposure Prediction Models Risk-Based Prioritization

Paradigm Shift EDSP21 TSCA21 FIFRA21 Estrogen Androgen Thyroid +Additional Estrogen Androgen Thyroid +Additional